Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

18.50
-1.7700-8.73%
Pre-market: 18.750.2500+1.35%08:15 EDT
Volume:3.78M
Turnover:70.82M
Market Cap:1.78B
PE:-3.17
High:19.40
Open:19.36
Low:18.29
Close:20.27
52wk High:42.37
52wk Low:18.29
Shares:96.48M
Float Shares:92.79M
Volume Ratio:1.60
T/O Rate:4.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8316
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-22.03%
PB:-22.31
PE(LYR):-3.17

Loading ...

OverviewCompanyNewsFilings

Ultragenyx Pharma Is Maintained at Buy by B of A Securities

Dow Jones
·
Jan 03

Two Phase 3 Trial Failures Halve Stock Price; Jefferies Sees Ultragenyx (RARE.US) Rebounding in 2026 with Pipeline Candidates, Initiates "Buy" Rating

Stock News
·
Dec 31, 2025

Ultragenyx Completes Rolling BLA Submission to FDA for DTX401 Gene Therapy

Reuters
·
Dec 31, 2025

Ultragenyx Completes Rolling Submission of Biologics License Application (Bla) to U.S. FDA for Dtx401 Aav Gene Therapy for Glycogen Storage Disease Type Ia (Gsdia)

THOMSON REUTERS
·
Dec 31, 2025

Wall Street's Top Analysts Latest Ratings: DigitalBridge Downgraded

Deep News
·
Dec 31, 2025

Ultragenyx Pharma Is Maintained at Buy by Jefferies

Dow Jones
·
Dec 30, 2025

The Market Doesn't Like What It Sees From Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Revenues Yet As Shares Tumble 43%

Simply Wall St.
·
Dec 30, 2025

Ultragenyx Pharmaceutical Inc : Piper Sandler Cuts Target Price to $75 From $105

THOMSON REUTERS
·
Dec 30, 2025

Brand Engagement Network, Ultragenyx, Cemtrex, Sidus Space And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Benzinga_recent_news
·
Dec 30, 2025

Barclays Cuts Price Target on Ultragenyx Pharmaceutical to $44 From $50, Keeps Overweight Rating

MT Newswires Live
·
Dec 30, 2025

Ultragenyx Pharmaceutical Down Over 44%, on Track for Record Low Close And Record Percent Decrease -- Data Talk

Dow Jones
·
Dec 30, 2025

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Dow Jones
·
Dec 30, 2025

Top Midday Stories: DigitalBridge to Be Acquired by SoftBank; Ultragenyx's Brittle Bone Disease Drug Studies Miss Primary Endpoints

MT Newswires Live
·
Dec 30, 2025

Wedbush Adjusts Price Target on Ultragenyx Pharmaceutical to $23 From $35, Maintains Neutral Rating

MT Newswires Live
·
Dec 30, 2025

Ultragenyx's Bone Disease Drug Fails to Improve Fracture Rate in Late-Stage Trials

Reuters
·
Dec 29, 2025

Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows

Benzinga_recent_news
·
Dec 29, 2025

Update: Ultragenyx Shares Fall After Brittle Bone Disease Studies Fail to Achieve Primary Endpoints

MT Newswires Live
·
Dec 29, 2025

US Stock Alert | Ultragenyx Pharmaceutical (RARE.US) Plummets Over 42% Pre-Market After Late-Stage Trial Failure for Investigational Genetic Bone Disease Drug

Stock News
·
Dec 29, 2025

Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga_recent_news
·
Dec 29, 2025

Ultragenyx Pharma Shares Fall 42.6% Premarket After Bone Disease Drug Fails in Late-Stage Trials

THOMSON REUTERS
·
Dec 29, 2025
More